MAIA Biotechnology Q3 EPS Forecast Lowered by Diamond Equity

MAIA Biotechnology, Inc. (NYSEAMERICAN:MAIA) – Investment analysts at Diamond Equity decreased their Q3 2026 EPS estimates for MAIA Biotechnology in a report issued on Monday, August 17th. Diamond Equity analyst H. Diamond now anticipates that the company will post earnings of ($0.13) per share for the quarter, down from their previous forecast of ($0.12). The consensus estimate for MAIA Biotechnology’s current full-year earnings is ($0.52) per share. Diamond Equity also issued estimates for MAIA Biotechnology’s Q4 2026 earnings at ($0.14) EPS, FY2026 earnings at ($0.54) EPS, Q1 2027 earnings at ($0.15) EPS, Q2 2027 earnings at ($0.15) EPS and FY2027 earnings at ($0.48) EPS.

MAIA Biotechnology Stock Performance

Shares of NYSEAMERICAN:MAIA opened at $1.39 on Thursday. The stock has a 50 day moving average price of $1.37 and a 200-day moving average price of $1.47. The firm has a market capitalization of $84.55 million, a P/E ratio of -2.24 and a beta of 0.24. MAIA Biotechnology has a 52-week low of $0.87 and a 52-week high of $3.19.

MAIA Biotechnology (NYSEAMERICAN:MAIA) last issued its quarterly earnings data on Monday, August 10th. The company reported ($0.13) EPS for the quarter, missing the consensus estimate of ($0.11) by ($0.02).

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of MAIA. Centric Wealth Management bought a new position in MAIA Biotechnology during the 2nd quarter valued at about $1,107,000. PVG Asset Management Corp bought a new position in MAIA Biotechnology in the 1st quarter worth $46,000. Corsair Capital Management L.P. purchased a new position in shares of MAIA Biotechnology during the 1st quarter valued at about $140,000. Jane Street Group LLC purchased a new position in MAIA Biotechnology during the fourth quarter valued at approximately $120,000. Finally, Geode Capital Management LLC boosted its holdings in MAIA Biotechnology by 9.5% in the 4th quarter. Geode Capital Management LLC now owns 296,740 shares of the company’s stock worth $454,000 after buying an additional 25,684 shares during the period. 5.65% of the stock is owned by institutional investors.

Insider Activity

In related news, CEO Vlad Vitoc purchased 72,700 shares of MAIA Biotechnology stock in a transaction dated Monday, June 1st. The stock was purchased at an average cost of $1.39 per share, for a total transaction of $101,053.00. Following the completion of the acquisition, the chief executive officer directly owned 976,121 shares of the company’s stock, valued at $1,356,808.19. The trade was a 8.05% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, Director Stan Smith acquired 75,000 shares of MAIA Biotechnology stock in a transaction on Monday, June 1st. The shares were purchased at an average price of $1.34 per share, with a total value of $100,500.00. Following the completion of the purchase, the director owned 1,519,178 shares in the company, valued at $2,035,698.52. This represents a 5.19% increase in their position. The SEC filing for this purchase provides additional information. Insiders have purchased 149,700 shares of company stock worth $204,233 in the last three months. 19.81% of the stock is currently owned by insiders.

MAIA Biotechnology Company Profile

MAIA Biotechnology, Inc is a clinical‐stage biopharmaceutical company developing a proprietary platform for site‐specific conjugation of monoclonal antibodies with diagnostic and therapeutic radioisotopes. By leveraging precision radiochemistry, the company aims to enhance the safety and efficacy profiles of antibody‐based imaging agents and targeted radiotherapeutics. Its approach is designed to deliver high‐contrast tumor visualization through PET imaging as well as focused cytotoxicity in oncology indications.

The company’s pipeline includes several antibody‐radiotracer candidates optimized for the detection of distinct tumor biomarkers, with preclinical data showing favorable targeting specificity and improved pharmacokinetics compared to conventional methods.